The Oncology Institute, Inc.
TOI
$4.59
$0.122.69%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 3.86% | 3.95% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 3.86% | 3.95% | |||
| Cost of Revenue | 4.14% | 1.32% | |||
| Gross Profit | 2.42% | 20.32% | |||
| SG&A Expenses | 0.61% | 11.05% | |||
| Depreciation & Amortization | -0.98% | -5.28% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.42% | 2.94% | |||
| Operating Income | 5.70% | 14.24% | |||
| Income Before Tax | 66.81% | 54.51% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 66.81% | 54.51% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 66.81% | 54.51% | |||
| EBIT | 5.70% | 14.24% | |||
| EBITDA | 7.17% | 16.68% | |||
| EPS Basic | 67.46% | 55.20% | |||
| Normalized Basic EPS | 66.95% | 56.24% | |||
| EPS Diluted | 68.01% | 54.42% | |||
| Normalized Diluted EPS | 66.95% | 56.24% | |||
| Average Basic Shares Outstanding | 0.34% | 4.09% | |||
| Average Diluted Shares Outstanding | 0.34% | 4.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||